Bank Of Montreal

ProShares Ultra Bloomberg Natural Gas

Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily Small Cap Bull 3X ETF

Direxion Daily Semicondct Bull 3X ETF

ARK Innovation ETF

VS TR -1x Short VIX Futures ETF

Direxion Daily Financial Bull 3X ETF

United States Natural Gas

Guggenheim Solar ETF

VS TR 2x Long VIX Futures ETF

ProShares UltraShort Bloomberg Natrl Gas

Direxion Daily S&P Biotech Bear 3X ETF

ProShares Ultra VIX Short-Term Futures

Direxion Daily Small Cap Bear 3X ETF

Direxion Daily Semicondct Bear 3X ETF

Direxion Financial Bear 3X Shar

Direxion Daily 20+ Yr Trsy Bear 3X ETF

United States Oil Fund

Genworth Financial Inc Common Stock

Granite Point Mortgage Trust Inc. Common Stock

JinkoSolar Holding Company Limited American Depositary Shares (each representing 4 Common Shares)

RE/MAX Holdings Inc. Class A Common Stock

TKO Group Holdings Inc. Class A Common Stock

Gray Television Inc. Common Stock

QuantumScape Corporation Class A Common Stock

WESCO International Inc. Common Stock

Reddit Inc. Class A Common Stock

Carvana Co. Class A Common Stock

Allstate Corporation (The) Common Stock

Halliburton Company Common Stock

UBS Group AG Registered Ordinary Shares

Hecla Mining Company Common Stock

Telefonica SA Common Stock

ASGN Incorporated Common Stock

CVR Energy Inc. Common Stock

Spotify Technology S.A. Ordinary Shares

Valero Energy Corporation Common Stock

ServiceNow Inc. Common Stock

Click here to get full coverage on ACLX: HC Wainwright & Co. Reiterates Buy Rating with $115 Target | ACLX Stock News - GuruFocus

ACLX: HC Wainwright & Co. Reiterates Buy Rating with $115 Target | ACLX Stock News  GuruFocus

ACLX: HC Wainwright & Co. Reiterates Buy Rating with $115 Target | ACLX Stock News - GuruFocus

Click here to get full coverage on $ACLX stock is up 8% today. Here's what we see in our data. - Nasdaq

$ACLX stock is up 8% today. Here's what we see in our data.  Nasdaq

$ACLX stock is up 8% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Baron Discovery Fund Initiated a Position in Arcellx (ACLX) - Yahoo Finance

Baron Discovery Fund Initiated a Position in Arcellx (ACLX)  Yahoo Finance

Baron Discovery Fund Initiated a Position in Arcellx (ACLX) - Yahoo Finance

Click here to get full coverage on (ACLX) Technical Data - news.stocktradersdaily.com

(ACLX) Technical Data  news.stocktradersdaily.com

(ACLX) Technical Data - news.stocktradersdaily.com

Click here to get full coverage on Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - Business Wire

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma  Business Wire

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - Business Wire

Click here to get full coverage on Insiders At Arcellx Sold US$2.6m In Stock, Alluding To Potential Weakness - simplywall.st

Insiders At Arcellx Sold US$2.6m In Stock, Alluding To Potential Weakness  simplywall.st

Insiders At Arcellx Sold US$2.6m In Stock, Alluding To Potential Weakness - simplywall.st

Click here to get full coverage on Arcellx Impressive Safety Data Leaves Doubts (NASDAQ:ACLX) - Seeking Alpha

Arcellx Impressive Safety Data Leaves Doubts (NASDAQ:ACLX)  Seeking Alpha

Arcellx Impressive Safety Data Leaves Doubts (NASDAQ:ACLX) - Seeking Alpha

Click here to get full coverage on Arcellx (ACLX): Citi Initiates Buy Rating with Promising Outlook | ACLX Stock News - GuruFocus

Arcellx (ACLX): Citi Initiates Buy Rating with Promising Outlook | ACLX Stock News  GuruFocus

Arcellx (ACLX): Citi Initiates Buy Rating with Promising Outlook | ACLX Stock News - GuruFocus

Click here to get full coverage on Citigroup Initiates Arcellx at Buy With $110 Price Target - marketscreener.com

Citigroup Initiates Arcellx at Buy With $110 Price Target  marketscreener.com

Citigroup Initiates Arcellx at Buy With $110 Price Target - marketscreener.com

Click here to get full coverage on Here’s Why Arcellx (ACLX) Declined in Q1 - Insider Monkey

Here’s Why Arcellx (ACLX) Declined in Q1  Insider Monkey

Here’s Why Arcellx (ACLX) Declined in Q1 - Insider Monkey

Click here to get full coverage on Arcellx, Inc. (ACLX): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance

Arcellx, Inc. (ACLX): Among Takeover Rumors Hedge Funds Are Buying  Yahoo Finance

Arcellx, Inc. (ACLX): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance

Click here to get full coverage on Arcellx Provides First Quarter 2025 Financial Results and Business Highlights - Business Wire

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights  Business Wire

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights - Business Wire

Click here to get full coverage on ARCELLX Earnings Results: $ACLX Reports Quarterly Earnings - Nasdaq

ARCELLX Earnings Results: $ACLX Reports Quarterly Earnings  Nasdaq

ARCELLX Earnings Results: $ACLX Reports Quarterly Earnings - Nasdaq

Click here to get full coverage on We Think Arcellx (NASDAQ:ACLX) Can Easily Afford To Drive Business Growth - simplywall.st

We Think Arcellx (NASDAQ:ACLX) Can Easily Afford To Drive Business Growth  simplywall.st

We Think Arcellx (NASDAQ:ACLX) Can Easily Afford To Drive Business Growth - simplywall.st

Click here to get full coverage on Is Arcellx, Inc. (ACLX) An Oversold Biotech Stock to Buy Now? - Yahoo Finance

Is Arcellx, Inc. (ACLX) An Oversold Biotech Stock to Buy Now?  Yahoo Finance

Is Arcellx, Inc. (ACLX) An Oversold Biotech Stock to Buy Now? - Yahoo Finance

Click here to get full coverage on ACLX June 20th Options Begin Trading - Nasdaq

ACLX June 20th Options Begin Trading  Nasdaq

ACLX June 20th Options Begin Trading - Nasdaq

Click here to get full coverage on Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference - Business Wire

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference  Business Wire

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference - Business Wire

Click here to get full coverage on Arcellx (ACLX): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential - Yahoo Finance

Arcellx (ACLX): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential  Yahoo Finance

Arcellx (ACLX): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential - Yahoo Finance

Click here to get full coverage on Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates  Yahoo Finance

Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Business Wire

Annual Oncology Innovation Summit and Its Investor Event During EHA2025  Business Wire

Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Business Wire

Click here to get full coverage on Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors - Business Wire

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors  Business Wire

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors - Business Wire

Click here to get full coverage on Arcellx Announces Positive Phase 2 Study Results - TipRanks

Arcellx Announces Positive Phase 2 Study Results  TipRanks

Arcellx Announces Positive Phase 2 Study Results - TipRanks

Click here to get full coverage on Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights - Business Wire

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights  Business Wire

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights - Business Wire

Click here to get full coverage on Transcript : Arcellx, Inc. - Special Call - marketscreener.com

Transcript : Arcellx, Inc. - Special Call  marketscreener.com

Transcript : Arcellx, Inc. - Special Call - marketscreener.com

Click here to get full coverage on Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition - Business Wire

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition  Business Wire

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition - Business Wire

Click here to get full coverage on Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. - Investor's Business Daily

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.  Investor's Business Daily

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. - Investor's Business Daily

Click here to get full coverage on Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights - Business Wire

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights  Business Wire

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights - Business Wire

Click here to get full coverage on Arcellx director Kavita Patel sells shares worth $86,250 - Investing.com

Arcellx director Kavita Patel sells shares worth $86,250  Investing.com

Arcellx director Kavita Patel sells shares worth $86,250 - Investing.com

Click here to get full coverage on Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday - Benzinga

Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday  Benzinga

Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday - Benzinga

Click here to get full coverage on 5 Biotech Breakthrough Stocks to Watch in 2025 - Yahoo Finance

5 Biotech Breakthrough Stocks to Watch in 2025  Yahoo Finance

5 Biotech Breakthrough Stocks to Watch in 2025 - Yahoo Finance

Click here to get full coverage on Arcellx earnings missed by $0.37, revenue fell short of estimates - Investing.com

Arcellx earnings missed by $0.37, revenue fell short of estimates  Investing.com

Arcellx earnings missed by $0.37, revenue fell short of estimates - Investing.com

Click here to get full coverage on Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma - Seeking Alpha

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma  Seeking Alpha

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma - Seeking Alpha

Click here to get full coverage on Arcellx names new board members, gears up for 2026 launch - Investing.com

Arcellx names new board members, gears up for 2026 launch  Investing.com

Arcellx names new board members, gears up for 2026 launch - Investing.com

Click here to get full coverage on arcellx director Kavita Patel sells shares worth $101,040 By Investing.com - Investing.com Nigeria

arcellx director Kavita Patel sells shares worth $101,040 By Investing.com  Investing.com Nigeria

arcellx director Kavita Patel sells shares worth $101,040 By Investing.com - Investing.com Nigeria

Click here to get full coverage on Arcellx Inc. Receives Buy Rating: Strong Financial Outlook and Promising Data Catalysts - TipRanks

Arcellx Inc. Receives Buy Rating: Strong Financial Outlook and Promising Data Catalysts  TipRanks

Arcellx Inc. Receives Buy Rating: Strong Financial Outlook and Promising Data Catalysts - TipRanks

Click here to get full coverage on Arcellx Provides Second Quarter 2024 Financial Results and Business Updates - Business Wire

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates  Business Wire

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates - Business Wire

Click here to get full coverage on Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday - Benzinga

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday  Benzinga

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday - Benzinga

Click here to get full coverage on Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights - PR Newswire

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights  PR Newswire

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights - PR Newswire

Click here to get full coverage on Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH - PR Newswire

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH  PR Newswire

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH - PR Newswire

Click here to get full coverage on Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results - PR Newswire

Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results  PR Newswire

Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results - PR Newswire

Click here to get full coverage on Strategic partnerships for the new Waikato Regional Theatre - cxnetwork.com.au

Strategic partnerships for the new Waikato Regional Theatre  cxnetwork.com.au

Strategic partnerships for the new Waikato Regional Theatre - cxnetwork.com.au

Click here to get full coverage on Arcellx Provides First Quarter 2024 Financial Results - Business Wire

Arcellx Provides First Quarter 2024 Financial Results  Business Wire

Arcellx Provides First Quarter 2024 Financial Results - Business Wire

Click here to get full coverage on Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market (NASDAQ:ACLX) - Seeking Alpha

Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market (NASDAQ:ACLX)  Seeking Alpha

Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market (NASDAQ:ACLX) - Seeking Alpha

Click here to get full coverage on Arcellx to Participate in Two Upcoming Investor Conferences - Business Wire

Arcellx to Participate in Two Upcoming Investor Conferences  Business Wire

Arcellx to Participate in Two Upcoming Investor Conferences - Business Wire

Click here to get full coverage on Scotiabank Initiates Coverage of Arcellx (ACLX) with Sector Outperform Recommendation - Nasdaq

Scotiabank Initiates Coverage of Arcellx (ACLX) with Sector Outperform Recommendation  Nasdaq

Scotiabank Initiates Coverage of Arcellx (ACLX) with Sector Outperform Recommendation - Nasdaq

Click here to get full coverage on Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition - PR Newswire

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition  PR Newswire

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition - PR Newswire

Click here to get full coverage on ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP - PR Newswire

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP  PR Newswire

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP - PR Newswire

Click here to get full coverage on Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program - PR Newswire

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program  PR Newswire

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program - PR Newswire

Click here to get full coverage on Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program - Business Wire

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program  Business Wire

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program - Business Wire

Click here to get full coverage on Gilead hands Arcellx $285M to expand BCMA cell therapy deal, sparking fresh push for congested market - Fierce Biotech

Gilead hands Arcellx $285M to expand BCMA cell therapy deal, sparking fresh push for congested market  Fierce Biotech

Gilead hands Arcellx $285M to expand BCMA cell therapy deal, sparking fresh push for congested market - Fierce Biotech

Click here to get full coverage on Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma - Business Wire

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma  Business Wire

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma - Business Wire

Click here to get full coverage on Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress - PR Newswire

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress  PR Newswire

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress - PR Newswire

Click here to get full coverage on Arcellx Announces Upsizing and Pricing of Follow-On Public Offering - PR Newswire

Arcellx Announces Upsizing and Pricing of Follow-On Public Offering  PR Newswire

Arcellx Announces Upsizing and Pricing of Follow-On Public Offering - PR Newswire

Click here to get full coverage on Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares - PR Newswire

Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares  PR Newswire

Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares - PR Newswire

Arcellx Inc (ACLX)

Price Chart

Key Statistics

Technicals

About ACLX

Latest News

ACLX: HC Wainwright & Co. Reiterates Buy Rating with $115 Target | ACLX Stock News - GuruFocus

$ACLX stock is up 8% today. Here's what we see in our data. - Nasdaq

Baron Discovery Fund Initiated a Position in Arcellx (ACLX) - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers